SCHEMBL4137035

SCHEMBL4137035

CC(C)(C)CNC(=O)c1ccc(N2CCC3(CC2)CCN(C2CCC2)CC3)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 5/20 0.46
▸ ALDH1A1 P00352 7/20 0.46
▸ SMN1; SMN2 Q16637 7/20 0.46
▸ RAB9A P51151 6/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ HPGD P15428 6/20 0.46
▸ NPC1 O15118 5/20 0.45
▸ TSHR P16473 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ CXCR3 P49682 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ HPGDS O60760 2/20 0.43
▸ TP53 P04637 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ KIF18A Q8NI77 1/20 0.42
▸ HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291009 0.90 HPGDS (0.49) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4139822 0.89 HRH3 (0.48) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4130249 0.87 ALDH1A1 (0.50) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4138981 0.86 HRH3 (0.46) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4137203 0.86 SMN1; SMN2 (0.52) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4130565 0.86 HRH3 (0.52) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4130511 0.85 ALDH1A1 (0.48) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4131259 0.85 MEN1 (0.46) HRH3SMN1; SMN2KDM4EMAPTLMNA
SCHEMBL4139827 0.85 SCD (0.51) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4129082 0.85 ALDH1A1 (0.48) HRH3ALDH1A1SMN1; SMN2RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 — — EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 — — WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 HRH3 1/4885ALDH1A1 734/4885SMN1; SMN2 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback